companydata.dkcompanydata.dk

NOVO NORDISK PHARMACEUTICALS A/S: Financial statements 2018

CVR: 24257924

Source: annual report 2018, Danish Business Authority

01/01/2018 – 31/12/2018

NOVO NORDISK PHARMACEUTICALS A/S (CVR 24257924) has filed annual accounts for 2018. In 2018, the company reported a net result of DKK -1,984,000 compared with DKK -2,285,000 the year before. Equity in the 2018 report amounted to DKK 11,847,000. The solvency ratio was 99.7%.

Profit/Loss
DKK -1,984,000
Equity
DKK 11,847,000
Total Assets
DKK 11,880,000

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2018---2M11.8M-
2017---2.3M13.8M-
2016--1.7M16.1M-
2015--1.9M14.4M-
2014--3.2M12.5M-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2018

Tomas Haagen joins the board of NOVO NORDISK PHARMACEUTICALS A/SOct 1, 2018

As of October 1, 2018, Tomas Haagen has joined the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.

Ole Falvig Ramsby leaves the board of NOVO NORDISK PHARMACEUTICALS A/SOct 1, 2018

As of October 1, 2018, Ole Falvig Ramsby has left the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.

NOVO NORDISK PHARMACEUTICALS A/S: The 2017 annual report is outMay 15, 2018

NOVO NORDISK PHARMACEUTICALS A/S has published its annual report for 2017. The net result was DKK -2,285,000.

Karsten Munk Knudsen joins the board of NOVO NORDISK PHARMACEUTICALS A/SApr 25, 2018

As of April 25, 2018, Karsten Munk Knudsen has joined the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.

Jesper Brandgaard leaves the board of NOVO NORDISK PHARMACEUTICALS A/SApr 25, 2018

As of April 25, 2018, Jesper Brandgaard has left the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.

Peter Bøggild joins NOVO NORDISK PHARMACEUTICALS A/S as directorApr 25, 2018

As of April 25, 2018, Peter Bøggild is registered as director of NOVO NORDISK PHARMACEUTICALS A/S.

Karsten Munk Knudsen steps down as director of NOVO NORDISK PHARMACEUTICALS A/SApr 25, 2018

As of April 25, 2018, Karsten Munk Knudsen has stepped down as director of NOVO NORDISK PHARMACEUTICALS A/S.

About NOVO NORDISK PHARMACEUTICALS A/S

NOVO NORDISK PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 1974. The company is registered under the industry Anden finansiel formidling i.a.n.. The company was previously named NOVO FARMAKA A/S. The management consists of Anders Rytter Mikkelsen. The board consists of Naja Eilers Barrisøe (chair), Linette Tangsgaard Nielsen and Thomas Rask Nielsen. The company is owned by NOVO NORDISK A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -53,000 and a net result of DKK 2,074,000 compared with DKK 6,918,000 the year before. Equity in the 2025 report amounted to DKK 12,325,000.

Source: annual report 2025, Danish Business Authority